Observational study suggests low disease reactivation risk in selected MOGAD patients, indicating potential treatment discontinuation.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Motte et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: